Editas Medicine Inc
EDITHealthcare|Biotechnology|USA
$3.26
-0.03 (-0.76%)
Tangible Book
$0.05
Upcoming Data Readouts (0)
No upcoming completion dates found in active trials.
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Sep 2025
P1P2
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
NCT05444894Aug 2025
P1P2
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
NCT04853576